Open-Label, to Evaluate the Efficacy and Safety of Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study: RITE Study
Latest Information Update: 10 Feb 2021
Price :
$35 *
At a glance
- Drugs Reslizumab (Primary) ; Corticosteroids; Prednisone
- Indications Churg-Strauss syndrome
- Focus Adverse reactions
- Acronyms RITE
- 03 Feb 2021 Results published in the Annals of Allergy, Asthma and Immunology
- 03 Feb 2021 Status has been changed to completed as per results published in the Annals of Allergy, Asthma and Immunology.
- 12 Sep 2017 Status changed from not yet recruiting to recruiting.